At the Medical University of South Carolina, researchers have made an important discovery that could change the way patients ...

The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.

Heart attacks have remained the leading cause of death in the United States for over a century. Most treatments focus on ...

Shares of Cumberland Pharmaceuticals (CPIX) doubled on Tuesday morning, reaching levels not seen since March 2023, following ...

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

A research team led by the University of Liverpool has developed an innovative new technique that can rapidly assess ...

L-methylfolate calcium (Metafolin) 6mg, Algae-S powder 90.314mg, methylcobalamin 2mg, N-acetylcysteine 600mg; caplets. Avoid if renal stones occur. Do not administer to critically ill patients ...

On Monday, the FDA approved Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) supplemental New Drug Application (sNDA) for its ...

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a ...

The major findings of this study of exacerbations of COPD can be summarised as follows: (a) among patients with elevated CRP, those receiving NAC were more likely to have this marker normalised ...